Chronic HIV-2 infection protects against total CD4+ cell depletion and rapid disease progression induced by SHIV89.6p challenge

AIDS

Volumn 18, Issue 8, 2004, Pages 1127-1135

  Otten, Ron A ^a   Adams, Debra R ^a   Kim, Caryn N ^a   Pullium, Jennifer K ^a,b   Sawyer, Tamela ^a   Jackson, Eddie ^c   Folks, Thomas M ^a   Butera, Sal ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

CD4; HIV; Pig tailed macaque; Re challenge; Simian human immunodeficiency virus

Indexed keywords

IMMUNOGLOBULIN; RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; CROSS REACTION; FOLLOW UP; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; INOCULATION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MACACA; MEDICAL ASSESSMENT; MOLECULAR MIMICRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROVOCATION TEST; REINFECTION; SPECIES COMPARISON; UTERINE CERVIX CYTOLOGY; VIRUS INFECTION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; FEMALE; HIV INFECTIONS; HIV-2; LYMPHOPENIA; MACACA NEMESTRINA; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 2942555172     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200405210-00006     Document Type: Article

References (36)

1. Travers K, Mboup S, Marlink R, Gueye-Nidaye A, Siby T, Thior I, et al. Natural protection against HIV-1 infection provided by HIV-2. Science 1995; 268:1612-1615.
2. Greenberg AE, Wiktor SZ, DeCock KM, Smith P, Jaffe HW, Dondero TJ, Jr. HIV-2 and natural protection against HIV-1 infection. Science 1996; 272:1959-1960.
3. Wiktor SZ, Nkengasong JN, Ekpini ER, Adjorlolo-Johnson GT, Ghys PD, Brattegaard K, et al. Lack of protection against HIV-1 infection among women with HIV-2 infection. AIDS 1999; 13:695-699.
4. Greenberg AE. Possible protective effect of HIV-2 against incident HIV-1 infection: review of available epidemiological and in vitro data. AIDS 2001; 15:2319-2321.
5. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group [see comments]. N Engl J Med 1997; 337:1485-1490.
6. Katz MH, Gerberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use [see comments]. N Engl J Med 1997; 336:1097-1100.
7. Prevention CfDCa. Management of possible sexual, injecting-drug-use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy. Public Health Service statement. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1998; 47:1-14.
8. Prevention CfDCa. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1998; 47:1-33.
9. Lurie P, Miller S, Hecht F, Chesney M, Lo B. Postexposure prophylaxis after nonoccupational HIV exposure: clinical, ethical, and policy considerations [see comments]. JAMA 1998; 280:1769-1773.
10. Tsai CC, Emau P, Follis KE, Beck TW, Benveniste RE, Bischofberger N, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72:4265-4273.
11. Van Rompay KK, Berardi CJ, Aguirre NL, Bischofberger N, Lietman PS, Pedersen NC, et al. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS 1998, 12:F79-83.
12. Otten RA, Smith DK, Adams DR, Pullium JK, Jackson E, Kim CN, et al. Efficacy of post-exposure prophylaxis (PEP) after intravaginal exposure of pig-tailed macaques with a human-derived retrovirus (HIV-2). J Virol 2000; 74:9771-9775.
13. Otten RA, Brown BG, Simon M, Lupo LD, Parekh BS, Lairmore MD, et al. Differential replication and pathogenic effects of HIV-1 and HIV-2 in Macaca nemestrina. AIDS 1994; 8:297-306.
14. Otten RA, Ellenberger DL, Adams DR, Fridlund CA, Jackson E, Pieniazek D, et al. Identification of a window period for susceptibility to dual infection with two distinct human immunodeficiency virus type 2 isolates in a Macaca nemestrina (pig-tailed macaque) model. J Infect Dis 1999; 180:673-684.
15. Pullium JK, Adams DR, Jackson E, Kim CN, Smith DK, Janssen R, et al. Pig-tailed macaques infected with human immunodeficiency virus (HIV) type 2GB122 or simian/HIV89.6p express virus in semen during primary infection: new model for genital tract shedding and transmission. J Infect Dis 2001; 183:1023-1030.
16. Yang C, Pieniazek D, Owen SM, Fridlund C, Nkengasong J, Mastro TD, et al. Detection of phylogenetically diverse human immunodeficiency virus type 1 groups M and O from plasma by using highly sensitive and specific generic primers. J Clin Microbiol 1999; 37:2581-2586.
17. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994; 32:292-300.
18. Lu FX, Ma Z, Rourke T, Srinivasan S, McChesney M, Miller CJ. Immunoglobulin concentrations and antigen-specific antibody levels in cervicovaginal lavages of rhesus macaques are influenced by the stage of the menstrual cycle. Infect Immun 1999; 67:6321-6328.
19. Rappaport J, Arya SK, Richardson MW, Baier-Bitterlich G, Klotman PE. Inhibition of HIV-1 expression by HIV-2. J Mol Med 1995; 73:583-589.
20. Arya SK, Gallo RC. Human immunodeficiency virus (HIV) type 2-mediated inhibition of HIV type 1: a new approach to gene therapy of HIV-infection. Proc Natl Acad Sci USA 1996; 93:4486-4491.
21. Al-Harthi L, Owais M, Arya SK. Molecular inhibition of HIV type 1 by HIV type 2: effectiveness in peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 1998; 14:59-64.
22. Kokkotou EG, Sankale JL, Mani I, Gueye-Ndiaye A, Schwartz D, Essex ME, et al. In vitro correlates of HIV-2-mediated HIV-1 protection. Proc Natl Acad Sci USA 2000; 97:6797-6802.
23. Nkengasong JN, Kestens L, Ghys PD, Koblavi-Deme S, Otten RA, Bile C, et al. Dual infection with human immunodeficiency virus type 1 and type 2: impact on HIV type 1 viral load and immune activation markers in HIV-seropositive female sex workers in Abidjan, Ivory Coast. AIDS Res Hum Retroviruses 2000; 16:1371-1378.
24. Lifson JD, Rossio JL, Piatak M, Jr., Parks T, Li L, Kiser R, et al. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol 2001; 75:10187-10199.
25. Smith MS, Foresman L, Lopez GJ, Tsay J, Wodarz D, Lifson JD, et al. Lasting effects of transient postinoculation tenofovir [9-R-(2- Phosphonomethoxypropyl)adenine] treatment on SHIV(KU2) infection of rhesus macaques. Virology 2000; 277:306-315.
26. Kaul R, Plummer F, Clerici M, Bomsel M, Lopalco L, Broliden K. Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS 2001; 15:431-432.
27. Belec L, Ghys PD, Hocini H, Nkengasong JN, Tranchot-Diallo J, Diallo MO, et al. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-séronégative African women. J Infect Dis 2001; 184:1412-1422.
28. Devito C, Hinkula J, Kaul R, Lopalco L, Bwayo JJ, Plummer F, et al. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000; 14:1917-1920.
29. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292:69-74.
30. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine 2002; 20:1949-1955.
31. hu infected macaques. Virology 2000; in press.
32. Putkonen P, Thorstensson R, Albert J, Hild K, Norrby E, Biberfeld P, et al. Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection. AIDS 1990; 4:783-789.
33. Putkonen P, Walther L, Zhang YJ, Li SL, Nilsson C, Albert J, et al. Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine. Nat Med 1995; 1:914-918.
34. Walther-Jallow L, Nilsson C, Soderlund J, ten Haaft P, Makitalo B, Biberfeld P, et al. Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys. J Gen Virol 2001; 82:1601-1612.
35. Ellerbrock TV, Lennox JL, Clancy KA, Schinazi RF, Wright TC, Pratt-Palmore M, et al. Cellular replication of human immuno-deficiency virus type 1 occurs in vaginal secretions. I Infect Dis 2001; 184:28-36.
36. Coombs RW, Reichelderfer PS, Landay AL. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 2003; 17:455-480.